How to buy Purple Biotech stock

Purple Biotech Ltd is a biotechnology business based in the US. Purple Biotech shares (PPBT) are listed on the NASDAQ and all prices are listed in US Dollars.

Purple Biotech share price

Use our graph to track the performance of PPBT stocks over time.

Purple Biotech shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$0.22 - $7.25
50-day moving average	$4.94
200-day moving average	$4.39
Wall St. target price	$25.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Purple Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Purple Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Purple Biotech Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Purple Biotech financials

Revenue TTM	$1 million
Gross profit TTM	$1 million
Return on assets TTM	-16%
Return on equity TTM	-61.97%
Profit margin	0%
Book value	N/A
Market capitalisation	$72.8 million

TTM: trailing 12 months

Shorting Purple Biotech shares

There are currently 314,116 Purple Biotech shares held short by investors – that's known as Purple Biotech's "short interest". This figure is 11% down from 353,122 last month.

There are a few different ways that this level of interest in shorting Purple Biotech shares can be evaluated.

Purple Biotech's "short interest ratio" (SIR)

Purple Biotech's "short interest ratio" (SIR) is the quantity of Purple Biotech shares currently shorted divided by the average quantity of Purple Biotech shares traded daily (recently around 1.4 million). Purple Biotech's SIR currently stands at 0.22. In other words for every 100,000 Purple Biotech shares traded daily on the market, roughly 220 shares are currently held short.

However Purple Biotech's short interest can also be evaluated against the total number of Purple Biotech shares, or, against the total number of tradable Purple Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Purple Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Purple Biotech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Purple Biotech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Purple Biotech.

Find out more about how you can short Purple Biotech stock.

Purple Biotech share dividends

We're not expecting Purple Biotech to pay a dividend over the next 12 months.

Purple Biotech share price volatility

Over the last 12 months, Purple Biotech's shares have ranged in value from as little as $0.2198 up to $7.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Biotech's is 2.0372. This would suggest that Purple Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Purple Biotech overview

Purple Biotech Ltd. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.

Frequently asked questions

• What percentage of Purple Biotech is owned by insiders or institutions?

  Currently 1.913% of Purple Biotech shares are held by insiders and 14.486% by institutions.

• When does the fiscal year end for Purple Biotech?

  Purple Biotech's fiscal year ends in December.

• Where is Purple Biotech based?

  Purple Biotech's address is: One Azrieli Center, Tel Aviv, Israel, 6701101